First National Bank of Omaha Buys Shares of 2,910 Thermo Fisher Scientific Inc. $TMO

First National Bank of Omaha purchased a new position in Thermo Fisher Scientific Inc. (NYSE:TMO) in the 3rd quarter, Holdings Channel.com reports. The institutional investor purchased 2,910 shares of the medical research company’s stock, valued at approximately $1,411,000.

A number of other large investors also recently bought and sold shares of TMO. Axxcess Wealth Management LLC lifted its holdings in Thermo Fisher Scientific by 9.6% during the third quarter. Axxcess Wealth Management LLC now owns 27,191 shares of the medical research company’s stock worth $13,188,000 after buying an additional 2,374 shares during the period. Ingalls & Snyder LLC lifted its stake in shares of Thermo Fisher Scientific by 19.1% during the 3rd quarter. Ingalls & Snyder LLC now owns 2,951 shares of the medical research company’s stock worth $1,431,000 after purchasing an additional 474 shares during the last quarter. Cornerstone Advisory LLC boosted its position in Thermo Fisher Scientific by 27.8% during the third quarter. Cornerstone Advisory LLC now owns 962 shares of the medical research company’s stock valued at $467,000 after purchasing an additional 209 shares in the last quarter. Crestwood Advisors Group LLC grew its stake in Thermo Fisher Scientific by 4.7% in the third quarter. Crestwood Advisors Group LLC now owns 99,793 shares of the medical research company’s stock valued at $48,400,000 after purchasing an additional 4,484 shares during the last quarter. Finally, NEOS Investment Management LLC lifted its position in shares of Thermo Fisher Scientific by 28.6% during the third quarter. NEOS Investment Management LLC now owns 51,364 shares of the medical research company’s stock valued at $24,913,000 after buying an additional 11,415 shares during the last quarter. Institutional investors own 89.23% of the company’s stock.

Thermo Fisher Scientific Price Performance

Thermo Fisher Scientific stock opened at $514.03 on Thursday. The company’s 50 day simple moving average is $581.74 and its 200-day simple moving average is $545.34. Thermo Fisher Scientific Inc. has a 1 year low of $385.46 and a 1 year high of $643.99. The company has a market capitalization of $193.12 billion, a price-to-earnings ratio of 28.98, a price-to-earnings-growth ratio of 2.89 and a beta of 0.93. The company has a debt-to-equity ratio of 0.67, a quick ratio of 1.53 and a current ratio of 1.89.

Thermo Fisher Scientific (NYSE:TMO) last released its earnings results on Thursday, January 29th. The medical research company reported $6.57 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $6.45 by $0.12. The company had revenue of $12.22 billion for the quarter, compared to analyst estimates of $11.95 billion. Thermo Fisher Scientific had a net margin of 15.05% and a return on equity of 16.92%. The firm’s quarterly revenue was up 7.2% on a year-over-year basis. During the same period in the prior year, the business earned $6.10 EPS. As a group, equities research analysts expect that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific declared that its board has authorized a stock repurchase program on Thursday, November 6th that authorizes the company to buyback $5.00 billion in shares. This buyback authorization authorizes the medical research company to reacquire up to 2.4% of its shares through open market purchases. Shares buyback programs are usually a sign that the company’s board believes its stock is undervalued.

Wall Street Analysts Forecast Growth

TMO has been the subject of several recent analyst reports. Evercore restated an “outperform” rating and issued a $650.00 target price on shares of Thermo Fisher Scientific in a research note on Monday, January 5th. Wells Fargo & Company set a $683.00 price objective on Thermo Fisher Scientific in a research report on Friday, January 30th. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating on shares of Thermo Fisher Scientific in a research report on Thursday, October 23rd. KeyCorp raised Thermo Fisher Scientific from a “sector weight” rating to an “overweight” rating and set a $750.00 price target for the company in a report on Sunday, December 7th. Finally, Barclays upped their price objective on shares of Thermo Fisher Scientific from $625.00 to $650.00 and gave the company an “overweight” rating in a report on Friday, January 30th. One analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and two have given a Hold rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $633.68.

Insider Buying and Selling at Thermo Fisher Scientific

In related news, EVP Gianluca Pettiti sold 400 shares of the stock in a transaction on Monday, February 9th. The shares were sold at an average price of $541.20, for a total transaction of $216,480.00. Following the completion of the sale, the executive vice president owned 20,752 shares in the company, valued at $11,230,982.40. This represents a 1.89% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Michael D. Shafer sold 10,725 shares of the stock in a transaction dated Tuesday, November 25th. The stock was sold at an average price of $600.00, for a total transaction of $6,435,000.00. Following the transaction, the executive vice president directly owned 18,731 shares of the company’s stock, valued at $11,238,600. This represents a 36.41% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 108,996 shares of company stock valued at $63,355,935. 0.33% of the stock is currently owned by insiders.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.